Metagenomi Therapeutics (MGX) Change in Acquisitions & Divestments (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Change in Acquisitions & Divestments for 4 consecutive years, with $40.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 13.83% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $163.9 million (down 12.73% YoY), while the FY2025 annual figure was $170.5 million, down 22.99% from the prior year.
• Change in Acquisitions & Divestments slipped to $40.8 million in Q1 2026 per MGX's latest filing, from $52.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $101.5 million in Q4 2023 and bottomed at $33.5 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $53.6 million across 4 years, with a median of $47.3 million in 2025.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 81.62% in 2024 and fell as far as 59.38% in 2024.
• Metagenomi Therapeutics' Change in Acquisitions & Divestments stood at $101.5 million in 2023, then tumbled by 59.38% to $41.2 million in 2024, then rose by 26.15% to $52.0 million in 2025, then fell by 21.62% to $40.8 million in 2026.
• Business Quant data shows MGX's Change in Acquisitions & Divestments at $40.8 million in Q1 2026, $52.0 million in Q4 2025, and $33.5 million in Q3 2025.